

RUNX3 gene in renal cell cancer

Sir,

Dear Editor, we read the publication on “The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor” with a great interest. Parmar *et al.* concluded that “Lower expression of RUNX3 in renal cancer suggests its tumor suppressive role” [1]. In fact, the role of RUNX3 is well clarified in several malignancies. It is no doubt there is the similar observation for the case of renal cell carcinoma. In the present report, there are some limitations as noted by Parmar *et al.* [1]. An important consideration is the possible concurrent effect of another genetic factor that might modify the final phenotypic manifestation [2]. In case of RUNX3, the effect of concurrent p53 is well clarified and should be studied [3].

Beuy Joob¹, Viroj Wiwanitkit²

¹Sanitation 1, Medical Academic Center, Bangkok, Thailand, ²Department of Tropical Medicine, Hainan Medical University, China

Correspondence to: Beuy Joob, Sanitation1, Medical Academic Center, Bangkok, Thailand.
E-mail: beuyjoob@hotmail.com

References

1. Parmar KM, Singla M, Mandal AK, Bhattacharya S, Singh SK. The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor. *Int J Mol Immuno Oncol.* 2017; 2(2): 73 – 77.
2. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. *Oncogene.* 2004 May 24;23(24):4336-40.
3. Lee JW, van Wijnen A, Bae SC. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras? *Adv Exp Med Biol.* 2017;962:321-332.

How to cite this article: Joob B, Wiwanitkit V. RUNX3 gene in renal cell cancer. *Int J Mol Immuno Oncol* 2018;3:35.

Source of Support: Nil. **Conflict of Interest:** None declared.